ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0008

Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice

Biji T Kurien1, Devavrat Dave1, Martha Tsaliki1, Valerie Lewis1 and R Hal Scofield2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma City Veterans Affairs Medical Center, Oklahoma City, OK

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), autoantigens, autoimmune diseases, Mouse Models, Other, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0001–0008) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sjögren’s Disease is an autoimmune condition in which patients exhibit decreased salivary/lacrimal gland function and express autoantibodies that target the 60k molecular weight Ro autoantigen. Published works have proposed autoantibodies that target M3R as potential clinical markers for Sjögren’s Disease. Our studies show that 4-hydroxy-2-nonenal (lipid oxidation byproduct) immunized rabbits develop antibodies against G-protein-coupled acetylcholine receptor muscarinic-type-3-receptor (M3R) second (ECL2) and third (ECL3) extracellular loops. We hypothesized that there will be a differential induction of antibodies against ECL2 or ECL3 dependent on the degree of 4-hydroxy-2-nonenal (HNE)-modification of Ro60 in BALB/c mice.

Methods: Five groups of BALB/c mice were used in this study. Group I was immunized with Ro60. Groups II to IV were immunized with Ro60, modified with 0.4 mM (low), 2 mM (medium) and 10 mM (high) HNE respectively. Group V controls received Freund’s adjuvant. Antibodies to M3R ECL2 (amino acids 213-228) and ECL3 (amino acids 514-527) were detected by multiple antigenic peptide ELISA using sera from the immunized mice.

Results: Immunization with unmodified Ro60 induced a rapid and differential intermolecular epitope spreading to the second loop of M3R, but not to the third loop. Bleed 2 sera from Group 1 mice immunized with unmodified Ro60 had an average reactivity of OD405 0.69±0.3 to ECL2 peptide, while Group 2 mice immunized with low HNE-Ro60 showed an average reactivity of OD405 0.58±0.21. The medium HNE-Ro60 immunized mice (Group 3) had the highest reactivity (OD405 1.02±0.39), and the Freund’s control group (Group 5) had the lowest reactivity (OD405 0.01±0.06), while Group 3 mice immunized with high-HNE-Ro60 had a reactivity of OD405 0.25±0.11 to the ECL2 peptide. The anti-ECL2 antibody levels induced in the medium HNE-Ro60 group was significantly higher than the levels induced by immunization with unmodified Ro60 (p< 0.0003). The anti-ECL2 levels correlated well with the induction of anti-Ro60 and anti-La antibodies in the mice immunized with medium HNE-Ro60. A similar trend was observed in Bleed 6 of the five experimental groups, with the medium HNE-Ro60 immunized group having significantly higher anti-ECL2 antibody levels compared to Ro60 immunized group (p< 0.0005). However, there was no significant induction of antibodies to ECL3 in any of the groups for both bleeds.

Conclusion: We found a differential induction of antibodies against the second extracellular loop of M3R, with Group 3 mice immunized with medium HNE-Ro60 developing significantly higher reactivity when compared to all other groups. Such a differential intermolecular epitope spreading may have significant implications for developing a deeper understanding of the progression of autoimmunity in Sjögren’s Disease.


Disclosures: B. Kurien: None; D. Dave: None; M. Tsaliki: None; V. Lewis: None; R. Scofield: None.

To cite this abstract in AMA style:

Kurien B, Dave D, Tsaliki M, Lewis V, Scofield R. Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/differential-induction-of-anti-muscarinic-type-3-receptor-antibodies-by-immunization-with-4-hydroxy-2-nonenal-modified-ro60-in-balb-c-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-induction-of-anti-muscarinic-type-3-receptor-antibodies-by-immunization-with-4-hydroxy-2-nonenal-modified-ro60-in-balb-c-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology